Sandoz Family’s Emasan AG Sells Novartis Stake for $2.9 Billion in Major Cash-Out

Emasan AG, the investment arm of the Sandoz family, has sold a significant stake in Swiss pharmaceutical giant Novartis (SIX:NOVN), generating 2.6 billion Swiss francs ($2.90 billion).

The sale, conducted through an accelerated bookbuilding process, saw Emasan AG offload 26.5 million Novartis shares at 98.25 Swiss francs each. Goldman Sachs, acting as the bookrunner, confirmed the transaction on Wednesday.

This move marks a substantial capital realization for Emasan AG, highlighting a strategic shift in the investment portfolio of the Sandoz family. Novartis, a global leader in pharmaceuticals, has been a key holding for Emasan AG, making this divestment particularly notable for investors tracking the Swiss stock market.

The deal is expected to impact Novartis’s share performance, given the scale of the transaction. Market analysts are closely watching how this sell-off influences investor sentiment and Novartis’s future stock valuation.

This article was generated with AI assistance and reviewed by an editor.